BÖTTCHER CHOTIMA (DE)
| WO2001000019A1 | 2001-01-04 |
| US20070231306A1 | 2007-10-04 |
D. K. FOGG: "A Clonogenic Bone Marrow Progenitor Specific for Macrophages and Dendritic Cells", SCIENCE, vol. 311, no. 5757, 6 January 2006 (2006-01-06), pages 83 - 87, XP055154901, ISSN: 0036-8075, DOI: 10.1126/science.1117729
MATTHEW R RITTER ET AL: "Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 116, no. 12, 1 December 2006 (2006-12-01), pages 3266 - 3276, XP007911481, ISSN: 0021-9738, DOI: 10.1172/JCI29683
RAPPOLD I ET AL: "Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 1, no. 90, 1 July 1997 (1997-07-01), pages 111 - 125, XP002080672, ISSN: 0006-4971
PRINZ M ET AL: "Tickets to the brain: Role of CCR2 and CX3CR1 in myeloid cell entry in the CNS", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 224, no. 1-2, 27 July 2010 (2010-07-27), pages 80 - 84, XP027168962, ISSN: 0165-5728, [retrieved on 20100722]
PRILLER JOSEF ET AL: "Targeting gene-modified hematopoietic cells to the central nervous system: Use of green fluorescent protein uncovers microglial engraftment", NATURE MEDICINE, vol. 7, no. 12, December 2001 (2001-12-01), pages 1356 - 1361, XP002751966, ISSN: 1078-8956
| Claims 1. A bone marrow-derived myeloid progenitor cell (MPC), preferably an isolated bone marrow-derived myeloid progenitor cell (MPC), wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD34, c-Kit (CDl 17) and CX3CR1. 2. The bone marrow-derived myeloid progenitor cell (MPC) of claim 1, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CDl 15 and/or CD 135, preferably the bone marrow-derived myeloid progenitor cell (MPC) is expressing CDl 15 and CD135. 3. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 2, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CCR2. 4. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 3, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD38. 5. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 4, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD34, CX3CR1, CCR2, CD 117, CDl 15 and CD 135. 6. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 5, wherein the bone marrow-derived myeloid progenitor cell (MPC) is CD34+Scal" CX3CR1+CCR2+CD117+CD115+CD135+. 7. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 6, wherein the bone marrow-derived myeloid progenitor cell (MPC) is SSC10 and/or FSC10. 8. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 7, wherein the bone marrow-derived myeloid progenitor cell (MPC) is IL-17Ra-negative. 9. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 8, wherein the bone marrow-derived myeloid progenitor cell (MPC) is negative for at least one B-cell marker, preferably at least one membrane-bound B-cell marker, at least on T cell marker, at least one mature myeloid cell marker, at least one granulocyte / monocyte marker, at least one granulocyte marker and/or at least one erythrocyte marker. 10. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 9, wherein the bone marrow-derived myeloid progenitor cell (MPC) is a recombinant bone marrow-derived myeloid progenitor cell (MPC), preferably the recombinant bone marrow- derived myeloid progenitor cell (MPC) comprises a heterologous nucleic acid. 1 1. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 10, wherein the bone marrow-derived myeloid progenitor cell (MPC) is labelled with a therapeutically active isotope, preferably a therapeutically active radioisotope. 12. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 10, wherein the bone marrow-derived myeloid progenitor cell (MPC) is labelled with a diagnostically active label, preferably the label is an isotope, more preferably a diagnostically active radioisotope. 13. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 12, wherein the bone marrow-derived myeloid progenitor cell (MPC) is a human bone marrow- derived myeloid progenitor cell (hMPC). 14. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 13, for use in a method for treating a subject suffering from a disease or being at risk of suffering from a disease. 15. The bone marrow-derived myeloid progenitor cell (MPC) of claim 14, wherein the method is adoptive transfer of the myeloid progenitor cell (MPC) derived from bone marrow or mobilized human peripheral blood stem cells, preferably adoptive transfer in the treatment of the disease. 16. The bone marrow-derived myeloid progenitor cell (MPC) of claim 14, wherein the disease is a neurological or psychiatric disease, preferably a neurodegenerative disease. 17. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 13, for use in a method for treating a subject suffering from a disease or being at risk of suffering from a disease, wherein the bone marrow-derived myeloid progenitor cell (MPC) is a recombinant bone marrow-derived myeloid progenitor cell (MPC) delivering a therapeutically active agent into the subject. 18. The bone marrow-derived myeloid progenitor cell (MPC) of any one of claim 1 to 13, for use in a method for diagnosing a disease in a subject. 19. The bone marrow-derived myeloid progenitor cell (MPC) of claim 18, wherein the disease is a disease of the CNS, or an inflammatory disease. 20. A pharmaceutical composition comprising a bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 13 and a pharmaceutically acceptable excipient. 21. A diagnostic composition comprising a bone marrow-derived myeloid progenitor cell (MPC) of any one of claims 1 to 13 and a diagnostically acceptable excipient. 22. A kit comprising a bone marrow-derived myeloid progenitor cell (MPC) according to any one of claims 1 to 13 and at least one constituent selected from the group comprising a container, a buffer, a diluent, an excipient and an instruction leaflet. |
The present invention is related to a bone marrow-derived myeloid progenitor cell (MPC); the bone marrow-derived myeloid progenitor cell (MPC) for use in a method for treating a subject suffering from a disease or being at risk of suffering from a disease; the bone marrow-derived myeloid progenitor cell (MPC) for use in a method for treating a subject suffering from a disease or being at risk of suffering from a disease, wherein the bone marrow-derived myeloid progenitor cell (MPC) is a recombinant bone marrow-derived myeloid progenitor cell (MPC) delivering a therapeutically active agent into the subject; the bone marrow-derived myeloid progenitor cell (MPC) for use in a method for diagnosing a disease in a subject; a pharmaceutical composition comprising the bone marrow-derived myeloid progenitor cell (MPC); use of the bone marrow-derived myeloid progenitor cell (MPC) for the manufacture of a medicament; use of the bone marrow-derived myeloid progenitor cell (MPC) for the manufacture of a diagnostic agent; a method for the treatment of a disease, wherein the method comprises administering to a subject the bone marrow-derived myeloid progenitor cell (MPC); and a method for the diagnosis of a disease, wherein the method comprises administering to a subject the bone marrow-derived myeloid progenitor cell (MPC).
Neurological and psychiatric diseases, including neurodegenerative diseases, are on the rise affecting the life of an increasing number of people. Many neuropsychiatric diseases are late- onset, meaning there are some factors that change as a person ages for each disease. One constant factor is that in each disease, neurons gradually lose function. The process of neurodegeneration is not well understood so the diseases that stem from it have, as yet, no cures. However, clinical trials are performed pursuing a plurality of approaches in the treatment of neurodegenerative diseases.
One of such approaches is the use of cell transplants, whereby the transplanted cells exhibit certain surface markers. Some of these cell types, their progenitors and markers are discussed in the following. Tao-Sheng L. et al. (Am J Physiol Heart Circ Physiol 285: H931-H937, 2003) reported that CD 117+ stem cells played a key role in the therapeutic angiogenesis inducted by bone marrow cell implantation. According to Ritter M.R. et al. (J.Clin.Invest. 1 16: 3266-3276, 2006), myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. International patent application WO 01/00019 discloses a substantially enriched mammalian hematopoietic cell subpopulation which exhibits progenitor cell activity for myeloid lineages but which lack the potential to differentiate into lymphoid lineages. Rappold I. et al. (Blood, 90: 111-125, 1997) characterized core blood and bone marrow subsets expressing FLT3 (CD 135) receptor tyrosine kinase in terms of their function and phenotype. Auffray C. et al. (J. Exp. Med. 206: 595-606, 2009) reported on CX 3 CR1 + expression and its association with the commitment of CSF-1 + myeloid precursors to the macrophage/dendritic cell (DC) lineage. Akashi K. et al. (Nature, 404: 193-197, 2000) identified a clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Fogg D.K. et al. (Science 311 : 83-87, 2006) identified a clonogenic bone marrow progenitor that is specific for macrophages and dendritic cells. US patent application 2007/231306 discloses an isolated myeloid-like cell population comprising a majority of cells that are lineage-negative, and which express both CD44 antigen, CD66 antigen, CD1 lb antigen and hypoxia inducible factor lalpha (HIF-lalpha).
The problem underlying the present invention is thus the provision of means and methods for the treatment of neuronal diseases and neurodegenerative diseases in particular. A further problem underlying the present invention is the provision of means and methods for the diagnosis of neuronal diseases and neurodegenerative diseases in particular.
These and other problems underlying the present invention are solved by the subject matter of the attached independent claims. Preferred embodiments may be taken from the attached dependent claims. Also, the problem underlying the present invention is solved by the following embodiments and their subject matter:
Embodiment 1 : A bone marrow-derived myeloid progenitor cell (MPC), wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD34 and c- it (CD117).
Embodiment 2: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 1, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CX3 CR 1. Embodiment 3 : The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 2, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD115.
Embodiment 4: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 3, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD115 and CX3CR1.
Embodiment 5: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 4, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD 135.
Embodiment 6: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 5, preferably of any one of embodiments 1 and 2, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD115, CD135 and CX3CR1.
Embodiment 7: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 6, preferably of any one of embodiments 1, 2 and 6, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CCR2.
Embodiment 8: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 7, preferably of any one of embodiments 1 and 2, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CCR2 and CX3CR1.
Embodiment 9: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 8, preferably of any one of embodiments 1 and 2, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CCR2 and CD115.
Embodiment 10: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 9, preferably of any one of embodiments 1 and 2, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CCR2 and CD 135. Embodiment 11 : The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 10, preferably of embodiment 1, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CCR2, CX3CR1, CD115 and CD 135.
Embodiment 12: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 11, preferably of any one of embodiments 1, 2, 6 and 7, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD38.
Embodiment 13 : The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 12, preferably of any one of embodiments 1, 2, 6 and 7, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD38 and CD115.
Embodiment 14: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 13, preferably of any one of embodiments 1, 2, 6 and 7, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD38 and CD 135.
Embodiment 15: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 14, preferably of any one of embodiments 1, 2, 6 and 7, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD38 and CCR2.
Embodiment 16: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 15, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD38 and CX3CR1.
Embodiment 16: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 15, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD38, CD115 and CCR2.
Embodiment 17: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 16, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD38, CD135 and CCR2. Embodiment 18: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 17, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD38, CX3CR1 and CCR2.
Embodiment 19: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 18, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD34, CD117, CX3CR1, CD115, CD135 and CCR2.
Embodiment 20: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 19, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD34, CD117, CX3CR1, CD115, CD135, CCR2 and CD38.
Embodiment 21 : The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 20, wherein the bone marrow-derived myeloid progenitor cell (MPC) is expressing CD34, CD117, CX3CR1, CD115, CD135, CCR2 and CD38 and is Seal " .
Embodiment 22: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 21, preferably fo any one of embodiments 1, 2, 6, 7, 12, 19, 20 and 21, wherein the bone marrow-derived myeloid progenitor cell (MPC) is IL-17Ra-negative.
Embodiment 23: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 22, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21 and 22, wherein the bone marrow-derived myeloid progenitor cell (MPC) is negative for at least one B-cell marker, preferably at least one membrane-bound B-cell marker.
Embodiment 24: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 23, wherein at least one B-cell marker is selected from the group comprising CD45R, CD 19, CD20, CD22 und B220.
Embodiment 25: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 24, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23 and 24, wherein the bone marrow-derived myeloid progenitor cell (MPC) is negative for at least one T-cell marker.
Embodiment 26: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 25, wherein the at least one T-cell marker is selected from the group comprising CD5, CD3, CD4 and CD8.
Embodiment 27: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 26, preferably o fany one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25 and 26, wherein the bone marrow-derived myeloid progenitor cell (MPC) is negative for at least one mature myeloid cell marker.
Embodiment 28: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 27, wherein the at least one mature myeloid cell marker is selected from the group comprising CD1 lb, CD 14, CD 16 and 7-4.
Embodiment 29: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 28, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27 and 28, wherein the bone marrow-derived myeloid progenitor cell (MPC) is negative for at least one granulocyte/monocyte marker.
Embodiment 30: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 29, wherein the at least one granulocyte/monocyte marker is selected from the group comprising Gr-1 and Ly6-G and Ly6-C.
Embodiment 31 : The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 30, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and 30, wherein the bone marrow-derived myeloid progenitor cell (MPC) is negative for at least one granulocyte marker. Embodiment 32: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 31, wherein, the at least one granulocyte marker is selected from the group comprising Ly6-G.
Embodiment 33: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 32, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32, wherein the bone marrow-derived myeloid progenitor cell (MPC) is negative for at least one erythrocyte marker.
Embodiment 34: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 33, wherein the at least one erythrocyte marker is selected from the group comprising Ter-119.
Embodiment 35: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 34, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 and 34, wherein the bone marrow-derived myeloid progenitor cell (MPC) is a recombinant bone marrow-derived myeloid progenitor cell (MPC).
Embodiment 36: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 35, wherein the recombinant bone marrow-derived myeloid progenitor cell (MPC) comprises a heterologous nucleic acid.
Embodiment 37: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 36, wherein the heterologous nucleic acid encodes a therapeutically active peptide, polypeptide or protein.
Embodiment 38: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 36, wherein the heterologous nucleic acid is a therapeutically active nucleic acid.
Embodiment 39: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 38, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 and 38, wherein the bone marrow-derived myeloid progenitor cell (MPC) is labelled with a therapeutically active isotope, preferably a therapeutically active radioisotope.
Embodiment 40: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 38, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 and 38, wherein the bone marrow-derived myeloid progenitor cell (MPC) is labelled with a diagnostically active label, preferably the label is an isotope, more preferably a diagnostically active radioisotope.
Embodiment 41 : The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 40, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 and 40, wherein the bone marrow- derived myeloid progenitor cell (MPC) is a human bone marrow-derived myeloid progenitor cell (hMPC).
Embodiment 42: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 41, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, for use in a method for treating a subject suffering from a disease or being at risk of suffering from a disease.
Embodiment 43 : The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 42, wherein the method is adoptive transfer of the myeloid progenitor cell (MPC) derived from bone marrow or mobilized human peripheral blood stem cells, preferably adoptive transfer in the treatment of the disease.
Embodiment 44: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 43, wherein the adoptive transfer is an allogeneic adoptive transfer.
Embodiment 45: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 44, wherein the adoptive transfer is an autologous adoptive transfer. Embodiment 46: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 43 to 45, wherein the adoptively transferred bone marrow-derived myeloid progenitor cell (MPC) is a recombinant bone marrow-derived myeloid progenitor cell (MPC).
Embodiment 47: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 42, wherein the disease is a neurodegenerative disease.
Embodiment 48: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 47, wherein the disease is an inflammatory nervous system disease.
Embodiment 49: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 47 to 48, wherein the disease is selected from the group comprising Alzheimer's disease, mild cognitive impairment, vascular dementia, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, Huntington's disease, Tourette syndrome, Parkinson's disease, multisystem atrophy, multiple sclerosis, stroke, epilepsy, autoimmune encephalitis, meningitis, migraine, leukodystrophy, inborn error of metabolism, brain/spinal cord injury, brain tumour, cranial/peripheral nerve injury, myopathy, polyneuropathy, major depression, bipolar disorder, attention deficit hyperactivity disorder, psychotic disorder including schizophrenia, autism/autism spectrum disorders, Rett syndrome, alcohol/drug addiction, anxiety disorder, eating disorder.
Embodiment 50: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 42 to 49, wherein the subject has not been subject to irradiation, preferably brain irradiation.
Embodiment 51 : The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 41, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, for use in a method for treating a subject suffering from a disease or being at risk of suffering from a disease, wherein the bone marrow-derived myeloid progenitor cell (MPC) is a recombinant bone marrow- derived myeloid progenitor cell (MPC) delivering a therapeutically active agent into the subject. Embodiment 52: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 51, wherein the therapeutically active agent is selected from the group comprising a peptide, a polypeptide and a protein.
Embodiment 53: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 51, wherein the therapeutically active agent is a therapeutically active nucleic acid.
Embodiment 54: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 51 to 53, wherein the therapeutically active agent is delivered into the central nervous system of the subject.
Embodiment 55: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiment 1 to 41, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, for use in a method for diagnosing a disease in a subject.
Embodiment 56: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 55, wherein the disease is a disease of the CNS.
Embodiment 57: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 55 to 56, wherein the disease is an inflammatory disease.
Embodiment 58: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiment 55 to 57, wherein the bone marrow-derived myeloid progenitor cell (MPC) is labeled with a detectable label.
Embodiment 59: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 58, wherein the detectable label is a magnetic nanoparticle or an isotope. Embodiment 60: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 59, wherein the isotope is a radioisotope.
Embodiment 61 : The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 60, wherein the method comprises a non-invasive detection step.
Embodiment 62: The bone marrow-derived myeloid progenitor cell (MPC) of embodiment 61, wherein the non-invasive detection step comprises imaging techniques, preferably the non-invasive detection step comprises CT and/or MRI and/or PET and/or SPECT.
Embodiment 63 : The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 42 to 62, wherein the bone marrow-derived myeloid progenitor cell (MPC) is administered to the subject by means of intravenous injection.
Embodiment 64: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 42 to 63, wherein the bone marrow-derived myeloid progenitor cell (MPC) is administered only once to the subject.
Embodiment 65: The bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 42 to 64, wherein the subject is a mammal, preferably a human.
Embodiment 66: A pharmaceutical composition comprising a bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 41, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and a pharmaceutically acceptable excipient.
Embodiment 67: The pharmaceutical composition for use in a method of treatment as defined in any of embodiments 42 to 54 and 63 to 65.
Embodiment 68: A method for the treatment of a disease, wherein the method comprises administering to a subject a bone marrow-derived myeloid progenitor cell (MPC) according to any one of embodiments 1 to 41, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, or a pharmaceutical composition according to any one of embodiments 66 to 67.
Embodiment 69: The method of embodiment 68, wherein the disease is a disease as defined in any one of embodiments 42 to 54.
Embodiment 70: A diagnostic composition comprising a bone marrow-derived myeloid progenitor cell (MPC) of any one of embodiments 1 to 41, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and a diagnostically acceptable excipient.
Embodiment 71: The diagnostic composition for use in a method of treatment as defined in any of embodiments 55 to 65.
Embodiment 72: A method for the diagnosis of a disease, wherein the method comprises administering to a subject a bone marrow-derived myeloid progenitor cell (MPC) according to any one of embodiments 1 to 41, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, or a diagnostic composition according to any one of embodiments 70 to 71.
Embodiment 73: The method of embodiment 72, wherein the disease is a disease as defined in any one of embodiments 42 to 54.
Embodiment 74: A kit comprising a bone marrow-derived myeloid progenitor cell (MPC) according to any one of embodiments 1 to 41, preferably of any one of embodiments 1, 2, 6, 7, 12, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and at least one constituent selected from the group comprising a container, a buffer, a diluent, an excipient and an instruction leaflet.
The present invention is based on the surprising finding that bone marrow-derived myeloid progenitor cells (MPCs) have a therapeutic effect, more specifically a therapeutic effect in neuropsychiatric disorders. Based on the findings and experimental evidence provided herein but without wishing to be bound by any theory, the present inventors conclude that bone marrow-derived myeloid progenitor cells (MPCs) give rise to myeloid cells that engraft in the central nervous system (CNS) after bone marrow/hem atopoietic stem cell (HSC) transplantation. In light thereof bone marrow-derived myeloid progenitor cells (MPCs) are a suitable means for cell-based gene therapy in the central nervous system (CNS). Furthermore, bone marrow-derived myeloid progenitor cells (MPCs) are superior to hematopoietic stem cells (HSCs) as they have a longer lifespan in blood and are present in higher quantity in the bone marrow.
Murine bone marrow-derived myeloid progenitor cells (MPCs) have been described in the prior art, for example, in Auffray et al. (Auffray et al.; J Exp Med. 2009, 206:595-606). Protocols for the identification of bone marrow-derived myeloid progenitor cells (MPCs) are described in Waskow et al. (Waskow et al., Nat. Immunol. 2008, 9:676 - 683) and Liu et al. (Liu et al., Science. 2009, 324:392-397). The identification protocols as described in Waskow et al. and Liu et al. are preferably used in connection with the instant application, whereby the surface antigens and, respectively, surface markers as disclosed herein are used for the characterization of bone marrow-derived myeloid progenitor cells (MPCs) and human bone marrow-derived myeloid progenitor cells (MPCs) in particular. Such surface antigens and, respectively, surface markers are also collectively referred to herein as such surface antigens, and such surface antigen and, respectively, surface marker is also collectively referred to herein as such surface antigen.
The terms bone marrow-derived myeloid progenitor cells and MPCs are interchangeably used herein.
As preferably used herein, bone marrow-derived myeloid progenitor cells (MPCs) are bone marrow-derived myeloid progenitor cells.
In an embodiment the bone marrow-derived myeloid progenitor cells (MPCs) are the ones described in the example part of the instant application and/or the ones which can be identified using the methods disclosed herein, including and in particular the methods described in the example part of the instant application.
The surface antigens used herein for the characterization of a bone marrow-derived myeloid progenitor cell (MPC) and more specifically of a bone marrow-derived myeloid progenitor cell (MPC) are preferably known in the art. Such surface antigen is preferably detected by an antibody, preferably a monoclonal antibody. In other words, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is detected and identified by an antibody binding to such surface antigen or by a plurality or multitude of antibodies binding to different such surface antigens.
In an embodiment the antibody binding to such surface antigen is one that is specifically binding to such surface antigen. An antibody specifically binding to such surface antigen is preferably one the binding of which is such that it does not cross-react with one or several other surface antigens existing on cells of the immune system, preferably of the immune system of a mammal and more preferably of the immune system of a human being. In a preferred embodiment the one or several other surface antigens existing on cells of the immune system are antigens that are used in the characterization of the various types and/or lineages of cells of the immune system.
Antibodies to such surface antigens are commercially available.
In an embodiment the antibody binding to such surface antigen and preferably used in the identification and/or detection of a bone marrow-derived myeloid progenitor cell (MPC) and a bone marrow-derived myeloid progenitor cell (MPC) of the invention in particular, comprises or bears a moiety which allows detection and/or identification of the antibody. Preferably, such detection and/or identification of the antibody allows detection and/or identification of a bone marrow-derived myeloid progenitor cell (MPC) and, in particular, a bone marrow- derived myeloid progenitor cell (MPC) of the invention.
In an embodiment, the moiety that allows detection and/or identification of the antibody is or comprises a label. Preferably such label allows cell sorting and more preferably fluorescence- activated cell sorting. In a preferred embodiment the moiety that allows detection and/or identification of the antibody is a fluorescent label.
In an embodiment where a bone marrow-derived myeloid progenitor cell (MPC) and, in particular, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is identified by a plurality or multitude of antibodies binding to different such surface antigens, it is preferred that the antibodies of the plurality of antibodies differ from each other as to their moieties that allow detection and/or identification of the antibody. Preferably the antibodies of the plurality of antibodies differ from each other as to their label, which is preferably a fluorescent label.
A bone marrow-derived myeloid progenitor cell (MPC) and, in particular, a bone marrow- derived myeloid progenitor cell (MPC) of the invention is preferably identified and/or detected using an antibody binding to such surface antigen, or by a plurality or multitude of antibodies binding to different such surface antigens together with flow cytometry. In a preferred embodiment flow cytometry is fluorescence-activated cell sorting which is also referred to as FACS. In an alternative embodiment flow cytometry is magnetic-activated cell sorting which is also referred to as MACS. It is within the present invention that when flow cytometry is used in the identification and/or detection of a bone marrow-derived myeloid progenitor cell (MPC) and, in particular, a bone marrow-derived myeloid progenitor cell (MPC) of the invention that the antibody, either individually or as a member of the plurality or multitude of antibodies, bears or comprises a moiety that allows detection and/or identification of the MPC.
It is within the instant invention that a bone marrow-derived myeloid progenitor cell (MPC) and, in particular, a bone marrow-derived myeloid progenitor cell (MPC) of the invention, is identified and/or detected by means of a compound which is specifically interacting with such surface antigen but which is different from an antibody. Such compound is preferably one selected from the group comprising an aptamer, a spiegelmer and an anticaline. Methods for the generation and use of such compounds are known in the art. It will be acknowledged by a person skilled in the art that such surface antigen is a target molecule for such compound. Aptamers are D-nucleic acids that are either single stranded or double stranded and which specifically interact with a target molecule. The generation and selection of aptamers is, e.g. described in European patent EP 0 533 838. Spiegelmers are L- nucleic acids that are either single stranded or double stranded and which specifically interact with a target molecule. The generation and selection of Spiegelmers is, e.g. described in WO 98/08856. Anticalines are target-binding polypeptides. Anticalines and methods for their generation and selection are, for example, described in German patent application DE 197 42 706.
It is within the present invention that such compounds which specifically interact with such surface antigen are used in the same way as described above for antibodies, and that such compounds which specifically interact with such surface antigen, are, as said antibodies, comprising or bearing a moiety which allows detection and/or identification of such compound.
According to the present invention, a bone marrow-derived myeloid progenitor cell (MPC) is expressing certain surface antigens. In an embodiment expressing a surface marker means that the surface marker is present in a cell or on a cell surface. Preferably, the surface marker is present on the cell. It will be acknowledged by a person skilled in the art that the degree of expression of a surface antigen may vary. The surface antigen may be expressed at a high level, a medium level or a low level. In a preferred embodiment of the instant invention the surface antigen is expressed at a high level. The degree of expression may be indicated in connection with such surface antigen. For example and for the purpose of illustration, CD34 hl indicates high expression of CD34, whereas CD34 lD indicates low expression of CD34. In an embodiment, the degree of expression can be determined in flow cytometry and FACS in particular, so that only those cells are identified, detected and/or sorted, i.e. removed from the remainder of the cells, which display a predefined expression of a given surface antigen.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) and, in particular, a bone marrow-derived myeloid progenitor cell (MPC) of the invention can also be characterized by certain surface antigens that are not been expressed by such cell. In a preferred embodiment such certain surface antigen is not expressed by such cell on the surface of such cell. The absence of such surface antigen can be detected by an antibody binding to such surface antigen and a compound binding to surface antigen, whereby the absence of such surface antigen is given in case such antibody and compound, respectively, is not binding to such cell.
A bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, and c-Kit (CD117).
A bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX 3 CR1.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), and CD115.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CX 3 CR1 and CD115.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), and CD 135.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CX 3 CR1 and CD135.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CCR2.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CX3CRI and CCR2.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17) and CD38. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c- it (CD117), CX 3 CR1 and CD38.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (GDI 17), CD115, CD135 and CX3CR1.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CX 3 CR1, CD115, CD135, CCR2 and CD38.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL- 17Ra-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD 135 and CX3CR1, but is IL-17Ra-negative. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD1 15 and CD 135, but is negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17), CD1 15 and CX3CR1, but is negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is IL-17Ra-negative and negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one T-cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD 135, but is negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one T-cell marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is IL-17Ra-negative and negative for at least one T-cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one B-cell marker and negative for at least one T-cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CDl 35, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one mature myeloid cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CX3CR1, but is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 135 and CX3CR1, but is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD 135, but is IL-17Ra-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD 135, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker.
Ia an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL- 17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD 135 and CX3CR1, but is IL- 17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one T-cell marker and at least one mature myeloid cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and negative for at least one T- cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115, CD 135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker. In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CDl 15 and CX3CR1, but is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL- 17Ra-negative and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marcow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 1 17) and CD 115, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 1 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD 135, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17), CD115 and CD 135, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 135 and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17), CD115, CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD 135, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 35 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CX3CR1, but is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17) and CD115, but is IL-17Ra-negative and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD 135, but is IL-17Ra-negative and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is lL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker. la an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 1 15, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17), CD115 and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker. In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17) and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 1 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL- 17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 1 15, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL- 17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 1 17), CD1 15 and CD 135, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1 , but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
Ini an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD1 15, CD135 and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD1 17), but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL- 17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD 135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 1 17) and CD 135, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD1 17), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD 135, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 35, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CDl 15 and CD 135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 35, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and negative for at least one T- cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD 135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD 135, but is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CDl 15 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17), CD115 and CD135, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD 135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL- 17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD 135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 35, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 135 and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 1 15, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD 135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD 135, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD 135, but is IL-17Ra-negative and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker, and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one T- cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one T-cell marker and at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17) and CD 135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c- it (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and negative for at least one B- cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c- it (CD 117) and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.,
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and negative for at least one B-cell marker and negative for at least one T-cell marker and negative for at least one mature myeloid cell marker and negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD 135 and CX3CR1, but is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD 135 and CX3CR1, but is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD 135, but is IL-17Ra-negative and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 1 17) and CD 1 15, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD 135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 135 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 1 17), CD 115, CD 135 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD 135, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one T-cell marker and at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD 135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL- 17Ra-negative and is negative for negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In. an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD 135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD1 15 and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD1 17), CD135 and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD 135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 1 17) and CD 135, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In. an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD 135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL- 17Ra-negative and is negative for at least one B-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CDl 15, CD 135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD 135, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 35, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD 135, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
I an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD117), but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CDl 15 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD 135, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
Ia an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 1 17) and CD 135, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD1 15 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CDl 15, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CD135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CD 135, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD 115, CD 135 and CX3CR1, but is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CDl 17), but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CDl 15, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17), CDl 15 and CD135, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CDl 17) and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD115, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CD135, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD135, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34 and c-Kit (CD 117), but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 115, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD 117) and CD 135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker. In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CD 135, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117) and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one granulocyte marker and is negative for at least one erythrocyte marker.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is expressing CD34, c-Kit (CD117), CD115, CD135 and CX3CR1, but is IL-17Ra-negative and is negative for at least one B-cell marker and is negative for at least one T-cell marker and is negative for at least one mature myeloid cell marker and is negative for at least one granulocyte/monocyte marker and is negative for at least one erythrocyte marker.
In an embodiment of the invention and in particular of any of the above embodiments specifying distinct combinations of surface antigens, at least one B-cell marker is a membrane-bound B-cell marker. In a preferred embodiment thereof at least one B-cell marker is selected from the group comprising CD45R, CD 19, CD20, CD22 and B220.
In an embodiment of the invention and in particular of any of the above embodiments specifying distinct combinations of surface antigens, at least one T-cell marker is selected from the group comprising CD5, CD3, CD4 and CD8.
In an embodiment of the invention and in particular of any of the above embodiments specifying distinct combinations of surface antigens, at least one mature myeloid cell marker is selected from the group comprising CD1 lb, CD 14, CD 16 and 7-4.
In an embodiment of the invention and in particular of any of the above embodiments specifying distinct combinations of surface antigens, at least one granulocyte/monocyte marker is selected from the group comprising Gr-1 and Ly6-G and Ly6-C.
In an embodiment of the invention and in particular of any of the above embodiments specifying distinct combinations of surface antigens, at least one granulocyte marker is selected from the group comprising Ly6-G.
In an embodiment of the invention and in particular of any of the above embodiments specifying distinct combinations of surface antigens, at least one erythrocyte marker is selected from the group comprising Ter-119.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention is a recombinant bone marrow-derived myeloid progenitor cell (MPC). In an embodiment of the present invention a recombinant bone marrow-derived myeloid progenitor cell (MPC) is a cell that has been subject to genetic engineering. In connection with such genetic engineering, the genome of the cell or the genetic information contained and/or expressed was changed compared to the wild type cell and/or compared to the genome of the cell prior to subjecting the same to genetic engineering. In an embodiment of the invention the genome of a recombinant comprises additional genetic information, less genetic information or different genetic information, in each case compared to the cell prior to subjecting the same to genetic engineering. In an embodiment a recombinant cell is one into which nucleic acid has been introduced which is as such is not present in the cell prior to subjecting the same to genetic engineering, or which as such is not expressed in the cell prior to subjecting the same to genetic engineering or which is present in the cell in a different regulatory context after subjecting the cell to genetic engineering. Such different regulatory context is, in an embodiment, realized by putting a nucleic acid which is transcribed and/or translated in the cell, under the control of a promoter which is different from the promoter which controls the expression in the cell prior to subjecting the same to genetic engineering. In a further embodiment such different regulatory context is realized by putting a nucleic acid which is transcribed and/or translated in the cell under the control of a regulatory RNA, such as an miRNA, which is different from the regulatory RNA that controls the expression in the cell prior to subjecting the same to genetic engineering.
In an embodiment a bone marrow-derived myeloid progenitor cell (MPC) of the invention comprises a heterologous nucleic acid. In an embodiment, a heterologous nucleic acid is a nucleic acid which is one is not present in and/or not expressed by the cell prior to subjecting the cell to genetic engineering. In a further embodiment, a heterologous nucleic acid is one which is present in the cell in a different regulatory context as illustrated above, compared to the regulatory context of such nucleic acid in the cell prior to subjecting the cell to genetic engineering.
In an embodiment the heterologous nucleic acid may code for a therapeutically active peptide, polypeptide or protein. In a preferred embodiment such therapeutically active peptide, polypeptide or protein is effective in the treatment of a disease in the treatment of which a bone marrow-derived of the invention is used. Preferably, the disease is one as disclosed herein. In an embodiment the heterologous nucleic acid may code for a therapeutically active nucleic acid. In a preferred embodiment such therapeutically active nucleic acid is effective in the treatment of a disease in the treatment of which a bone marrow-derived myeloid progenitor cell (MPC) of the invention is used. Preferably, the disease is one as disclosed herein.
In a further embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is labelled with a therapeutically active isotope. In preferred embodiment, the therapeutically active isotope is one selected from the group comprising 11 'in, 177 Lu, 89 Zr, 67 Ga, 68 Ga, 64 Cu and 90 Y.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is CD34 + Scal " CX 3 CR 1 + CCR2 + CD 117 + CD 115 + CD 135 + .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is a human bone marrow cell which is CD34 + ScarCX 3 CRl + CCR2 + CD117 + CD115 + CD135 + .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is a human G-CSF- mobilized peripheral blood cell which is CD34 + Scal "
CX 3 CPvl + CCR2 + CD 117 + CD 115 + CD 135 + .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a mouse bone marrow cell which is CD117-positive.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a mouse bone marrow cell which is Lin-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a mouse bone marrow cell which is CD44 hl .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a mouse bone marrow cell which is CD3e " CDl lb " CD45R B220TER119Xy6GXy6C " (Lin- negative). In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from mouse bone marrow cell which is lineage-negative and which expresses CD117
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from human bone marrow cell which expresses CD117 and which is lineage-negative.
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from human bone marrow cell which is CD34 + CD135 " .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from human bone marrow cell which is CD34 + CD135 + .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from human cord blood cell which is CD34 + CD135 " .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from human cord blood cell which is CD34 + CD135 + .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from mouse bone marrow cell which is Lin " CX 3 CRl + CDl 17 ,0 CD115 + CD135 + .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from mouse bone marrow cell which is Lin CX 3 CR1 CD117 .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from mouse bone marrow cell which is Lin " c kit^'CD 135 + CD 115 + CD34 + CD 11 c'°CD62L + CD24 + CD44 + AA4.1 l0 .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from mouse bone marrow cell which is Lin " c-kit hi CD135 + CX 3 CRl + CDl 15 + .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from mouse bone marrow cell which is Lin " CD115 + CD117 + NR4A2 hi . In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a mouse bone marrow cell which is Lin " CX 3 CRl + c-kit + CDl 15 + CD1 lb ' Grl " .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a mouse bone marrow cell which is CX 3 CR1 + CD117 + CD1 lb " Ly6C " .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a human bone marrow cell which is Lin " BDCA " CD123 " l0 CD34 + CD117 + CD135 + CD116 " CD115 + CD45 + CD45RA + CD38 + CD1 lc^HLA-DR + CDSS*" 1 .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a human cord blood cell which is Lin BDCA CD123 "/lo CD34 + CD117 + CD135 + CD116 " CD115 + CD45 + CD45RA + CD38 + CD1 lc^HLA-DR + CDSS 1 " 1 .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a human bone marrow cell which is Lin " CD34 + CD38 hi CD45RA + CD123 int CD10 " CD115 + CD116 " .
In an embodiment, a bone marrow-derived myeloid progenitor cell (MPC) is different from a human cord blood cell which is Lin " CD34 + CD38 hi CD45RA + CD123 int CD10 CDl 15 + CD116 " .
A pharmaceutical composition of the present invention comprises at least a bone marrow- derived myeloid progenitor cell (MPC) of the invention and, optionally, one or more carrier substances, excipients and/or adjuvants. The pharmaceutical composition may additionally comprise, for example, one or more of water, buffers such as, e.g., neutral buffered saline or phosphate buffered saline, ethanol, mineral oil, vegetable oil, dimethylsulfoxide, carbohydrates such as e.g., glucose, mannose, sucrose or dextrans, mannitol, proteins, adjuvants, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione and/or preservatives. Furthermore, one or more other active ingredients may, but need not, be included in the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be formulated for any appropriate route of administration, including, for example, parenteral administration. The term parenteral as used herein includes subcutaneous, intradermal, intravascular such as, e.g., intravenous, intramuscular, intrathecal and intra-arterial injection, as well as any similar injection or infusion technique. A preferred route of administration is intravenous administration.
A bone marrow-derived myeloid progenitor cell (MPC) of the invention and/or a pharmaceutical composition of the invention may be used in the treatment of a disease and/or in the treatment of a subject suffering from or being at risk of suffering from a disease. In a preferred embodiment the disease is a neurodegenerative disease.
In an embodiment the method of treatment is an adoptive transfer of a bone marrow-derived myeloid progenitor cell (MPC) of the invention. Such transfer can be either an allogeneic adoptive transfer or an autologous adoptive transfer. In case of an allogenic adoptive transfer, prior to administering to a subject the bone marrow-derived myeloid progenitor cell (MPC) of the invention or a pharmaceutical composition of the invention, matching between the donor subject and the recipient subject will be required. Typically, such matching is performed on the basis of HLA and the matching is HLA matching.
It is within the present invention that in an embodiment the bone marrow-derived myeloid progenitor cell (MPC) subject to adoptive transfer is actually a recombinant bone marrow- derived myeloid progenitor cell (MPC) of the invention. In a preferred embodiment, the recombinant bone marrow-derived myeloid progenitor cell (MPC) is one where one or several genetic defects have been corrected, whereby, preferably, in such embodiment the adoptive transfer is an autologous adoptive transfer.
The therapeutic use and applicability of a bone marrow-derived myeloid progenitor cell (MPC) of the invention and/or a pharmaceutical composition of the invention is based on the finding of the present inventors that a bone marrow-derived myeloid progenitor cell (MPC) of the invention gives rise to myeloid cells that engraft in the central nervous system (CNS), preferably after bone marrow/hematopoietic stem cell (HSC) transplantation. In light thereof, a bone marrow-derived myeloid progenitor cell (MPC) of the invention is a suitable means for cell-based therapy, preferably cell-based therapy in the CNS.
As shown in the example part of the instant application, neurodegenerative diseases that are characterized by dysfunction or loss of neurons and preferably progressive dysfunction or loss of neurons, can be treated by means of adoptive transfer of bone marrow-derived myeloid progenitor cells (MPCs) of the invention. Most importantly, such treatment was successful even when administered after onset of such neurodegenerative disease. Accordingly, the disease for the treatment of which a bone marrow-derived myeloid progenitor cell (MPC) of the invention may be used, is a neurodegenerative disease which is characterized by or goes along with dysfunction or loss of neurons, preferably progressive dysfunction or loss of neurons. Furthermore, as to the stage of such neurodegenerative disease in the treatment of which a bone marrow-derived myeloid progenitor cell (MPC) of the invention is used, in an embodiment of the present invention, said stage is one after onset of the disease. In accordance therewith, in an embodiment the subject which is to be treated in accordance with the present invention is one where the disease is manifest.
In connection with the results shown in the instant application for amyotrophic lateral sclerosis and Alzheimer's disease, such applicability of a bone marrow-derived myeloid progenitor cell (MPC) is plausible for neurodegenerative diseases and inflammatory diseases of the central nervous system. More specifically, it has been shown in the art that amyotrophic lateral sclerosis which is an inevitably fatal, adult-onset neurodegenerative disease characterized by progressive loss of both cortical and spinal motor neurons leading to muscle atrophy, paralysis, and death due to respiratory failure typically within 2-5 years can, in principle, be treated by anti-inflammatory drugs. Exemplary anti-inflammatory drugs and anti-inflammatory cells which were used in the treatment of amyotrophic lateral sclerosis include minocycline (Van Den Bosch et al. Neuroreport. 2002, 13:1067-1070), bone marrow- derived cells (Corti et al. Brain. 2004, 127:2518-2532; Corti et al. Hum Mol Genet. 2010, 19:3782-3796), or mesenchymal stem cells (MSCs) derived from bone marrow (Karussis et al. Arch Neurol. 2010, 67:1187-1194) or umbilical cord (Garbuzova-Davis et al. Plos One. 2012, 7:e31254). However, these studies failed to show therapeutic effects when the treatment was applied after disease onset. The present inventors showed that adoptive transfer of bone marrow-derived myeloid progenitor cells (MPCs) of the invention for treatment purposes after disease onset resulted in an attenuation of inflammatory pathology and delay in disease progression, extension of lifespan and improvement of motor activity. It has also been shown in the art that perivascular macrophages play a crucial role in amyloid (Αβ) clearance in Alzheimer's disease (Hawkes et al. PNAS. 2009, 106:1261-1266; Zaghi et al. Acta Neuropathol. 2009, 117:111-124; Mildner et al. J Neurosci. 2011, 31 :11159-11171; Michaud et al. Cell Rep. 2013, 5:646-653). The present inventors showed that adoptive transfer for treatment purposes of bone marrow-derived myeloid progenitor cells (MPCs) of the invention gave rise to perivascular macrophages in the brain, after intravenous injection, which allows amelioration of the condition of a subject suffering from Alzheimer's disease.
Without wishing to be bound by any theory, the mode of action of a bone marrow-derived myeloid progenitor cell (MPC) of the invention is based on an immunomodulatory and/or anti-inflammatory action.
In accordance therewith, a disease, for the treatment of which a bone marrow-derived myeloid progenitor cell (MPC) of the invention and/or a pharmaceutical composition of the invention may be used, is in an embodiment a disease which is selected from the group comprising Alzheimer's disease, mild cognitive impairment, vascular dementia, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, Huntington's disease, Tourette syndrome, Parkinson's disease, multisystem atrophy, multiple sclerosis, stroke, epilepsy, autoimmune encephalitis, meningitis, migraine, leukodystrophy, inborn error of metabolism, brain/spinal cord injury, brain tumour, cranial/peripheral nerve injury, myopathy, polyneuropathy, major depression, bipolar disorder, attention deficit hyperactivity disorder, psychotic disorder including schizophrenia, autism/autism spectrum disorders, Rett syndrome, alcohol/drug addiction, anxiety disorder and eating disorder.
Also in accordance therewith, a disease for the treatment of which a bone marrow-derived myeloid progenitor cell (MPC) of the invention and/or a pharmaceutical composition of the invention may be used, is any disease which goes along with or which is characterized and/or caused by a damage of the blood-brain barrier such as, for example, multiple sclerosis, stroke, Alzheimer's disease, encephalitis and meningo-encephalitis. In an embodiment of the various aspects of the present invention and more specifically the use of a bone marrow-derived myeloid progenitor cell (MPC) of the invention and a pharmaceutical composition for the treatment of a subject suffering from or being at risk of suffering from a disease, preferably a disease as disclosed herein, the subject is one which has not been subject to irradiation. Such subject is preferably one suffering from a disease or being at risk of suffering from a disease, whereby such disease is any disease which goes along with or is characterized and/or are caused by a damage of or a damaged blood-brain barrier such as, for example, multiple sclerosis, stroke, Alzheimer's disease, and (meningo-) encephalitis.
It is also within the present invention that apart from a therapeutic effect which arises immediately from a bone marrow-derived myeloid progenitor cell (MPC) of the invention, a therapeutic effect and/or an additional therapeutic effect can be created if a bone marrow- derived myeloid progenitor cell (MPC) of the invention is a recombinant bone marrow- derived myeloid progenitor cell (MPC) of the invention delivering a therapeutically active agent into a subject to which the recombinant bone marrow-derived myeloid progenitor cell (MPC) of the invention is administered. Such therapeutically active agent is typically one that is encoded by the recombinant bone marrow-derived myeloid progenitor cell (MPC) of the invention. In an embodiment, the therapeutically active agent is a peptide, a polypeptide or a protein. In another embodiment the therapeutically active agent is a therapeutically active nucleic acid. Such therapeutically active nucleic acid may be selected from the group comprising an aptamer, an antisense molecule, a ribozyme, an siRNA and other regulatory RNA, including but not limited to miRNA. The therapeutically active agent is one which is suitable for ameliorating the disease from which a subject to which such recombinant bone marrow-derived myeloid progenitor cell (MPC) of the invention is administered, is suffering or at risk of suffering. In an embodiment, the therapeutically active agent is an agonist, for example a peptide, a polypeptide or a protein. In a preferred embodiment the therapeutically active agent is a compound selected from the group comprising a growth factor and a neuroprotective agent. Preferably the growth factor is selected from the group comprising brain-derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF) and insulin-like growth factors (IGFs). Preferably, the neuroprotective agent is selected from the group comprising an erythropoietin (EPO), EPO variant and an antioxidant. In another embodiment the therapeutically active agent is an antagonist targeting a target molecule which when antagonized ameliorates the disease outcome. Such antagonist is, for example, an aptamer, an antisense molecule, a ribozyme, an siRNA or other regulatory RNA, including but not limited to miRNA.
It is within the present invention that a bone marrow-derived myeloid progenitor cell (MPC) of the invention, in particular a recombinant bone marrow-derived myeloid progenitor cell (MPC) of the invention, is suitable for or is actually delivering or is used for the delivery of a therapeutically active agent into the central nervous system of a subject to which such bone marrow-derived myeloid progenitor cell (MPC) of the invention is administered. In an embodiment, the thus delivered therapeutically active agent is a therapeutically active peptide, polypeptide or protein, as disclosed herein. In another embodiment, the thus delivered therapeutically active nucleic acid is a therapeutically active nucleic acid as disclosed herein. With regard to this aspect of the use of a bone marrow-derived myeloid progenitor cell (MPC) of the invention, it will be acknowledged by a person skilled in the art that such use is similar to the one of bone marrow-derived mesenchymal stromal cells (MSC).
In a further embodiment of a bone marrow-derived myeloid progenitor cell (MPC), the bone marrow-derived myeloid progenitor cell (MPC) is labelled with a detectable label. In a preferred embodiment the detectable label is a diagnostically active label. In a more preferred embodiment the diagnostically active label is selected from the group comprising a magnetic nanoparticle and an isotope. Magnetic nanoparticles which are suitable for use in a method of diagnosis, both an in vivo method of diagnosis and an in vitro method of diagnosis, are known to a person skilled in the art. In an embodiment the isotope is selected from the group comprising 113m In, 99ra Tc, 67 Ga, 52 Fe, 54 Fe, 68 Ga, 72 As, l u In, 97 Ru, 203 Pb, 62 Cu, 64 Cu, 51 Cr, 52m Mn, 157 Gd, 64 Cu, 89 Zr, 177 Lu, ,8 F, 19 F, 123 I, 124 I, 125 I, ,31 1, 75 Br, 76 Br, 77 Br, 82 Br, and 2U At.
The diagnostic composition of the invention comprises a bone marrow-derived myeloid progenitor cell (MPC) of the invention and a diagnostically acceptable excipient. In an embodiment, the bone marrow-derived myeloid progenitor cell (MPC) of the invention is a bone marrow-derived myeloid progenitor cell (MPC) of the invention that is labelled with a detectable label. Preferably, such label is a detectable label as disclosed herein. The diagnostically acceptable excipient is an excipient that allows the use of the diagnostic composition of the invention for the diagnosis of a disease. In an embodiment, the diagnostically acceptable excipient is an excipient as disclosed herein in connection with a pharmaceutical composition of the invention.
Without wishing to be bound by any theory, the diagnostic use of a bone marrow-derived myeloid progenitor cell (MPC) of the invention and/or of a diagnostic composition of the invention is based on the bone marrow-derived myeloid progenitor cell (MPC) being attracted to site of damage in the central nervous system, in particular inflammatory site. Due to the detectable label of a bone marrow-derived myeloid progenitor cell (MPC) of the invention such labeled bone marrow-derived myeloid progenitor cell (MPC) can be detected at the site of damage by a suitable detection device, preferably an imaging device and thus the site of damage be identified.
The diagnostic composition of the invention may be formulated for any appropriate route of administration, including, for example, parenteral administration. The term parenteral as used herein includes subcutaneous, intradermal, intravascular such as, e.g., intravenous, intramuscular, intrathecal and intra-arterial injection, as well as any similar injection or infusion technique. A preferred route of administration is intravenous administration.
A bone marrow-derived myeloid progenitor cell (MPC) of the invention and/or a diagnostic composition of the invention may be used in the diagnosis of a disease and/or in the diagnosis of a subject suffering from or being at risk of suffering from a disease. In a preferred embodiment the disease is a neurodegenerative disease. It is within the present invention that any disease disclosed herein in connection with the use of a bone marrow-derived myeloid progenitor cell (MPC) for the treatment of a disease is also a disease which can be diagnosed by the means and methods of the present invention and a bone marrow-derived myeloid progenitor cell (MPC) of the invention and/or a diagnostic composition of the invention in particular. It will be acknowledged that techniques and methods suitable for use in the diagnosis of a disease using a bone marrow-derived myeloid progenitor cell (MPC) of the invention and/or a diagnostic composition of the invention, are known to a person skilled in the art. In an embodiment, the method of diagnosis is a non-invasive diagnosis technique or comprises a non-invasive detection step. In a preferred embodiment the non-invasive detection step comprises one or any combination of computer tomography (CT), Magnetic resonance imaging (MRI), nuclear magnetic resonance imaging (NMRI), or magnetic resonance tomography (MRT), single photon emission computer tomography (SPECT) and/or Positron emission tomography (PET).
Dosages employed in practicing the methods for treatment and diagnosis, respectively, where bone marrow-derived myeloid progenitor cells (MPCs) of the invention are used and, respectively, administered to a subject will vary depending e.g. on the particular condition to be treated, and feature of the subject such as age, size and the like. A typical dosage and/or dose of bone marrow-derived myeloid progenitor cells (MPCs) of the invention administered to the subject is from 0.1 to 10 million bone marrow-derived myeloid progenitor cells (MPCs) or from 0.5 to 1 million bone marrow-derived myeloid progenitor cells (MPCs). It is within the present invention that in the treatment of a disease in accordance with the present invention only a single dose of bone marrow-derived myeloid progenitor cells (MPCs) is administered to a subject. It is also within the present invention that in the diagnosis of a disease in accordance with the present invention only a single dose of bone marrow-derived myeloid progenitor cells (MPCs) is administered to a subject.
In connection with each and any aspect of the present invention, a subject is preferably a mammal and more preferably a human being.
A kit according to the present invention comprising a bone marrow-derived myeloid progenitor cell (MPC) of the invention and at least one constituent selected from the group comprising a container, a buffer, a diluent, an excipient and an instruction leaflet. In an embodiment, the kit is a ready-for-use kit. In an embodiment the kit comprises a therapeutically active agent, preferable in case the kit is for therapeutic use, more preferably for use in a method of treatment of a disease as disclosed herein. In another embodiment the kit comprises a detectable label, preferable in case the kit is for diagnostic use, more preferably for use in a method of diagnosing a disease as disclosed herein.
It is within the present invention that any embodiment of a bone marrow-derived myeloid progenitor cell (MPC) as disclosed herein may be used in connection with the methods, uses, compositions and kits disclosed herein referring to, making use of and/or comprising a bone marrow-derived myeloid progenitor cell (MPC).
The present invention is now further illustrated by reference to the following figures and examples from which further advantages, features, and embodiments may be taken, wherein
Fig. la is a diagram illustrating the experimental set up for adoptive transfer of
HSCs, MPCs and monocytes, wherein a single cell population was intravenously injected into recipients that were previously conditioned with 11 Gy focal head irradiation (HI) and facial nerve axotomy (FNA); immunohistochemical and FACS analyses were performed at 1, 3, 7 and 14 days after transplantation;
Fig. lb is a panel of three diagrams indicating donor-derived cells in peripheral blood, bone marrow and spleen 1, 3, 7 and 14 days after adoptive transfer, wherein the left diagram is indicating HSCs as percentage of viable cells, the middle diagram is indicating MPCs as percentage of viable cells, and the right diagram is indicating inflammatory monocytes as percentage of viable cells (the error bar represents SEM);
Fig. lc is a panel of two diagrams indicating FACS analysis of gated
GFP + CDl lb " cells in BM and spleen of mice at 3 days after transplantation of GFP + HSCs; donor-derived cells remained scal + c-kit + Lin " (HSCs). Contour plot (in grey) represents host HSCs (GFP " );
Fig. Id is a panel of four diagrams indicating development of MPCs (scal " c- kit + Cdl l5 + CDl lb " ) from donor HSCs in blood (Bl) and BM at 7 and 14 days after transplantation. Contour plot (in grey) represents host MPCs (GFP " );
Fig. le is a panel of four diagrams indicating differentiation assays of HSCs in spleen and bone marrow (BM) by FACS; HSC-derived CDl lc + CDl lb + , CDl lc + CDl lb " , CDl lb + Ly6C hi CD115 + Gr-l l0 monocytes and CDl lb + Ly6C int CDl l5 " Gr- granulocytes were identified; Fig. If is a panel of eight diagrams indicating differentiation assays of donor
MPCs in bone marrow and spleen by FACS at 7 days after transplantation; DCs, macrophages (mO) and monocytes were identified, whereas no MPC-derived Gr-1 + neutrophils were detected;
Fig. 2a is a panel of six laser confocal microscopic images (scale bar: 25 μπι) showing the dorsal part of the brain stem of a focally head-irradiated mouse that was subjected to unilateral facial nerve axotomy followed by adoptive transfer of sorted MPCs (upper panel); the Iba-1 + GFP + and F4/80 + GFP + macrophages are pointed by arrow head and arrow, identifying donor-derived cells; nuclei are counterstained with DAPI; the contralateral unlesioned facial nucleus (white circle) shows minimal Iba-1 immunoreactivity compared to the ipsilateral facial nucleus (white square); the lower panel shows higher magnification images (scale bar: 100 μπι) of the axotomized facial nucleus in MPC-transplanted mice at days 1 (dl), 3 (d3), 7 (d7) and 14 (dl4) after transplantation; of note, the increase in Iba-1 immunoreactivity reveals increased inflammation with time; GFP + Iba-1 + cells were detected at 3, 7 and 14 days after transplantation (n = 3-5);
Fig. 2b is a panel of six laser confocal microscopic images indicating lack of engraftment of HSC-, monocyte-, cMoP-, MP-, CDP-, and Pre-cDC-derived cells in the lesioned facial nucleus at 14 days after adoptive transfer (scale bar: 100 μηι); no donor- derived GFP + cells were detected at any time point up to 14 days (n = 3-5);
Fig. 2c is a diagram showing quantification of donor-derived cell engraftment in the lesioned facial nucleus at 3, 7 and 14 days after transplantation; three to five mice were used per group, n.d. = not detected;
Fig. 2d is a diagram (left) and a laser confocal microscopic image (right) indicating the results of daily transplantations of Ly6C hl monocytes for five consecutive days; focally head-irradiated mice received a facial nerve axotomy and daily intravenous injections of lxlO 6 Ly6C hl monocytes for five consecutive days starting on day 1 after surgery; mice were sacrificed at 7 days after the first injection; FACS analysis of GFP + cells in peripheral blood revealed higher chimerism in mice receiving multiple (5x) injections of monocytes compared to a single injection (the error bar represents SEM); the left laser confocal microscopic image indicates that no monocyte-derived GFP + cells were found in the axotomized facial nucleus (scale bar: 100 μπι); three animals per groups were used; Fig. 2e consists of three laser confocal microscopic images (top) and a diagram (bottom) depicting the engraftment of MPC-derived cells in organotypic hippocampal slices. The engraftment of GFP + HSCs, MPCs, and monocytes was compared after culture on organotypic hippocampal slices. A quantitative evaluation is shown in the diagram. Note that MPCs gave rise to the highest levels of engraftment, whereas GFP + cells were rarely found in the slices after culture with monocytes and HSCs;
Fig. 3 a is a diagram indicating the role of chemokine receptor 2 (CCR2) for the homing of MPCs to the spleen; CCR2 " " or CCR2 +/+ MPCs that express GFP were intravenously injected into mice after focal head irradiation and facial nerve axotomy; seven and fourteen days after transplantation, engraftment of GFP + cells in the spleen was quantified by FACS; homing of MPCs to the spleen was reduced in the absence of CCR2 (n=3, means + SEM, unpaired t-test *p<0.05);
Fig. 3b is a laser confocal microscopic image of the axotomized facial nucleus of a focally head-irradiated mouse that received CCR2 7" GFP + MPCs. At 14 days after transplantation, no donor-derived GFP + cells were observed in the facial nucleus (scale bar: 100 μιη). The image showed Iba-1 + GFP " cells. Nuclei are counterstained with DAPI;
Fig. 3 c is a diagram showing the quantification of MPC-derived cells in different tissue compartments of mice that were intravenously injected with GFP + MPCs after focal head irradiation and facial nerve axotomy ; most GFP + cells were found in the spleen at 14 days after transplantation (n=5, means + SEM, unpaired t-test **p<0.01);
Fig. 3d is a diagram illustrating the experimental set up for adoptive transfer of
MPCs into mice that received focal head irradiation (HI), followed by splenectomy 12 days later and facial nerve axotomy (FNA) on day 13, i.e. one day prior to intravenous transplantation (Tx) of 2x10 4 sorted MPCs from GFP-expressing mice; immunohistochemical and FACS analyses were performed at 14 days after transplantation;
Fig. 3e is a laser confocal microscopic image (left) and a diagram (right) indicating the impact of splenectomy on the engraftment of MPC-derived GFP + cells in the axotomized facial nucleus; cells that gave positive immunoreactivity to Iba-1 and GFP are shown by arrow head; nuclei are counterstained with DAPI; scale bar: 100 μιη; MPCs do not require the passage through the spleen to engraft in the CNS;
Fig. 4a is a diagram illustrating the experimental set up for transplantation of
MPCs into Alzheimer's disease (AD) transgenic mice; APF '™ mice (8-9 months old) received focal head irradiation (HI) two weeks before intravenous transplantation (Tx) of 5xl0 5 GFP + MPCs; all animals, including non-transplanted PP^ we,PSl controls, received daily intraperitoneal injections of 1.5 mg/kg rapamycin; mice were analyzed at 4 weeks after transplantation;
Fig. 4b is a representative laser confocal microscopic image of the brain of an
App swe /p s i mouse at 4 weeks after transplantation of GFP + MPCs (scale bar: 100 μπι); GFP- expressing cells (arrow head) are exclusively found at perivascular sites; Αβ amyloid deposits are shown by arrow, endothelial cells are identified by CD31 immunoreactivity (*); nuclei are counterstained with DAPI; the right panel shows a higher magnification image and 3- dimensional analysis of the area indicated by the square in the confocal image;
Fig. 4c is a panel of four diagrams indicating the amounts of soluble and insoluble Αβι -40 and Αβι -42 as determined by ELISA in brain lysates from non- transplanted (white columns) and MPC-transplanted (black columns) APP i ™ e/psl animals at 4 weeks after transplantation; data are means + SEM from 3-4 mice per group; unpaired t-test *p<0.05;
Fig. 5a is a panel of two diagrams indicating short-term anti-inflammatory effects of MPCs in a transgenic mouse model of amyotrophic lateral sclerosis (ALS); Tg denotes non-irradiated SODl G93A transgenic mice (13-14 weeks old) that received either PBS (control) or a single intravenous injection of 5xl0 5 GFP + MPCs, followed by daily intraperitoneal injections of 1.5 mg/kg rapamycin for 4 weeks; the nervous system of the mice was analyzed by immunohistochemistry using the microglia/macrophage marker, Ibal, at 4 weeks after transplantation; MPC-treated S0D1 G 3A transgenic animals (Tg + MPCs, black columns) showed significantly less Iba-l-immunoreactive cells in the sciatic nerve and the spinal cord (lumbar region) compared with controls (means + SEM, n = 3, unpaired t-test, *p<0.05, **p<0.01);
Fig. 5b is a diagram depicting the motor performance of SODl G93A transgenic mice after transplantation of MPCs at 13-14 weeks of age (black squares) compared with non- transplanted S0D1 G93A transgenic mice (white squares) as determined by the rotarod test; MPC-transplanted mice showed significantly improved motor performance at more progressed stages of disease (n=6-8, means ± SEM, unpaired t-test, *p<0.05);
Fig. 5 c is a panel of two diagrams depicting the slowing of disease progression m SODl G93A transgenic mice after a single intravenous transplantation of MPCs at 13-14 weeks of age; Compared to the PBS-treated animals (Tg control, white columns), MPC- treated SOD1 transgenic mice (Tg + MPCs, black columns) showed delayed disease progression as indicated by the longer duration of the early disease phase (time at peak weight to time at 5% weight loss) and the longer duration of the late disease phase (time at > 5% weight loss to end stage) ( n=6-8, means + SEM, unpaired t-test, *p<0.05);
Fig. 5d are two images showing improved motor function in end-stage
SODl G93A transgenic mice after MPC transplantation; note that MPC-treated animals (Tg + MPCs) maintain the capacity to balance out with their hindlimbs, which non-transplanted SODl G93A transgenic mice (Tg control) cannot;
Fig. 5e is a laser confocal microscopic image depicting long-term engraftment of MPC-derived cells in the hindlimb musculature of SODl G93A transgenic mice; a GFP + cell (arrow head) that expresses the macrophage marker, Ibal (colocalized with GFP + cells, arrow head), is detected in the hindlimb musculature of a S0D1 G93A transgenic mouse at 10 weeks after transplantation of GFP + MPCs; nuclei are counterstained with DAPI, three-dimensional analysis of the high magnification image is provided;
Fig. 5f is a laser confocal microscopic image depicting long-term engraftment of MPC-derived cells in the sciatic nerve of S0D1 G93A transgenic mice; GFP cells (arrow head) that express the macrophage marker, Ibal (colocalized with GFP + cells, arrow head), are detected in the sciatic nerve of a SODl G93A transgenic mouse at 10 weeks after transplantation of GFP + MPCs; nuclei are counterstained with DAPI (blue); scale bar: 100 μη ; the right panel shows a higher magnification image of the area indicated by the square in the confocal image (upper panel for GFP + DAPI + cells; lower panel for Iba-1 + DAPI + cells);
Fig. 5g is a panel of two diagrams indicating long-term anti-inflammatory effects of MPCs in a transgenic mouse model of ALS; non-irradiated SODl G93A transgenic mice (13-14 weeks old) received either PBS (Tg control) or a single intravenous injection of 5xl0 5 GFP + MPCs (Tg + MPCs), followed by daily intraperitoneal injections of 1.5 mg/kg rapamycin until the end stage of disease (> 20% weight loss or failure of the mouse to right itself within 30 seconds); wild type mice (non Tg) served as controls; the nervous system of the mice was analyzed by immunohistochemistry using the microglia/macrophage marker, Ibal, at end stage of disease; MPC-treated SODl G93A transgenic animals (black columns) showed less Iba-l-immunoreactive cells in the sciatic nerve and the spinal cord (lumbar region) compared to non-transplanted S0D1 G93A transgenic mice (white columns); all groups of transgenic animals had significantly more Iba-l-immunoreactive cells in the sciatic nerve and the spinal cord (lumbar region) compared to wild type mice (grey columns) of comparable age and treatment (means + SEM, n = 3, One- Way ANOVA with Bonferroni's Test *p<0.05; **p<0.01 ; ***p<0.001);
Fig. 5h is a panel of six diagrams indicating attenuated expression of proinflammatory cytokines and chemokines in the nervous system of ALS transgenic mice after MPC transplantation; SODl G93A transgenic mice (13-14 weeks old) received either PBS (Tg control) or a single intravenous injection of 5xl0 5 GFP + MPCs (Tg + MPCs); quantitative real-time PCR analysis of CCL2, TNF-a, TGF-β, IL-6, IL-4 and IL-Ι β mRNA expression was performed in the spinal cords of Tg control (white columns) and Tg + MPCs (black columns) at end stage of disease; the mRNA expression levels were normalized to GAPDH mRNA and expressed as fold induction compared to non-transgenic wild type mice; MPC administration had significant anti-inflammatory effects in the CNS of ALS transgenic mice as indicated by the reduced gene expression of proinflammatory cytokines and chemokines in the spinal cord; data are means + SEM from 3 animals per group; statistical significance is indicated by asterisks (unpaired t-test *p<0.05; **p<0.01);
Fig. 6a is a diagram indicating that wild type, but not SOD1 mutant MPCs delay disease progression in ALS transgenic mice; non-irradiated SODl G93A transgenic mice (13-14 weeks old) received either PBS (Tg control, black triangles) or a single intravenous injection of 5xl0 5 MPCs from either SODl G93A transgenic mice (Tg + Tg MPCs, white squares) or non-transgenic wild type mice (Tg + wt MPCs, black squares), followed by daily intraperitoneal injections of 1.5 mg/kg rapamycin until the end stage of disease; motor performance of SODl G93A transgenic mice transplanted with wild type MPCs was significantly improved in the rotarod test at the end stage of disease compared with non- transplanted transgenic animals and SODl G93A transgenic mice transplanted with SOD1 mutant MPCs; data are means ± SEM from 3-4 animals per group; statistical significance is indicated by asterisks (unpaired t-test **p<0.01);
Fig. 6b is a diagram indicating that wild type, but not SOD1 mutant MPCs delay disease progression in ALS transgenic mice; weight loss of S0D1 G 3A transgenic mice transplanted with non-transgenic wild type MPCs (Tg + wt MPCs, black squares) was significantly attenuated during disease compared with non-transplanted SODl G93A transgenic animals (Tg control, black triangles) and SODl G93A transgenic mice transplanted with SOD1 mutant MPCs (Tg + Tg MPCs, white squares); data are means ± SEM from 3-4 animals per group. Statistical significance is indicated by asterisks (unpaired t-test *p<0.05; ***p<0.001);
Fig. 6c is a panel of two diagrams depicting the slowing of disease progression m SODl G93A transgenic mice transplanted with wild type MPCs; compared to the non- transplanted SOD1 transgenic animals (Tg control, white columns) and the SOD1 transgenic mice transplanted with MPCs from SODl G9iA transgenic mice (Tg + Tg MPCs, grey columns), SODl G93A transgenic mice transplanted with non-transgenic wild type MPCs (Tg + wt MPCs, black columns) showed delayed disease progression as indicated by the longer duration of the early disease phase (time at peak weight to time at 5% weight loss) and the longer duration of the late disease phase (time at > 5% weight loss to end stage) (3-4 animals per group, means + SEM, unpaired t-test, *p<0.05; **p<0.01 ; ***p<0.001).
Fig. 7a is a panel of six diagrams depicting the gating strategy for the identification of hematopoietic stem cells (HSCs), myeloid precursors (MPs), myeloid progenitor cells (MPCs) and common dendritic cell precursors (CDPs) by flow cytometry of murine bone marrow. Single Lin ~ (CD45R (B220), CD5, CDl lb, Gr-l(Ly6-G/C), Ly6-G, 7-4 and Ter-1 19 negative) cells were plotted for sca-1 and CDl 17 expression; CD117 + , sca-Γ precursors were then subdivided based on their expression of CDl 17 and CDl 15;
Fig. 7b is a diagram showing the expression of GFP (CX 3 CR1) in sorted HSCs,
MPs, MPCs and CDPs from the bone marrow of CX 3 CR1 GFP + mice;
Fig. 8 is a panel of six diagrams depicting the gating strategy for the identification of inflammatory monocytes (CDl lb + Ly6-C hl CDl 15 + ) and neutrophils (CDl lb + Ly6-C lo CD1 15 ~ Ly6-G + ) by flow cytometry of murine bone marrow; single Lin " (CD4, CD8a, CD19, Ter-119 negative) cells were plotted for CDl lb expression; CDl lb + cells were then subdivided based on their expression of Ly6-C and CDl 15; Ly6-G + cells of the Ly6C ,0 CDl 15 " population were then sorted;
Fig. 9a is a panel of three diagrams depicting the gating strategy for the identification of common monocyte progenitors (cMoPs; CD117 hi CD115 + CD135 " CDl lb " Ly6-C + ) and myeloid progenitor cells (MPCs; CD 1 17 hi CD 115 + CD 135 + CD 11 b " Ly6-C " ) by flow cytometry of murine bone marrow; cells were plotted for CDl 17 and CDl 15 expression; CD 1 17 m CD 1 15 + CD 1 1 b " cells were then subdivided based on their expression of Ly6-C and CD135; Fig. 9b is a panel of four diagrams indicating the differentiation of adoptively transferred cMoPs into monocytes, macrophages and CDl lb + CDl lc + cells in the spleen at 7 days after transplantation; donor-derived monocytes, macrophages, and CDl lb + CDl lc + cells were identified by flow cytometry in the spleen, whereas no CDl lc + CDl lb " DCs were detected;
Fig. 10 is a panel of four diagrams showing the characterization of human
MPCs by flow cytometry; a) CD34 + hematopoietic cells were isolated by magnetic-activated cell sorting from mobilized peripheral blood (frozen apheresis sample); no MPCs (SSC l0 FSC l0 CD45 l0 CD34 + CD115 + ) were detected in the sorted cell population before culturing; b) In the presence of growth factors (IL-3, IL-6, SCF, Flt31igand and GM-CSF) and serum-free medium, the majority of living cells in vitro were identified as SSC l0 FSC lo CD45 lo CD34 + (98.7 % of the entire cell population); 79.5 % of the SSC l0 FSC lo CD45 lo CD34 + cell population expressed the MPC marker, CD115 (CSF-1R), after differentiation in culture;
Fig. 11 is a composite panel of two diagrams and six laser confocal microscopic images illustrating the results of the ex vivo differentiation of human MPCs; frozen mobilized human peripheral blood stem cells obtained by apheresis (G-CSF PBSC) were cultured in the presence of growth factors (IL-3, IL-6, SCF, Flt31igand and GM-CSF) in serum-free medium for 3 days (div); the first diagram (left) depicts the gating strategy for the identification of myeloid precursor cells (MPCs) using flow cytometry; single SSC lo CD34 + was plotted for CD117 (c-kit) and CD115 expression; MPCs were sorted as SSC l0 FSC l0 CD34 + c-kit + CD115 + CD135 + cells (upper rectangle); the sorted SSC l0 FSC l0 CD34 + c-kit " CD115 " CD135 " cells served as a negative control population (lower left rectangle); the second diagram (right) shows the histogram plot of the expression of CD135 in sorted MPCs (unfilled histogram) and CD34 + CD115 " cells (grey-filled histogram); the sorted cells (2xl0 3 cells) were then cultured on the murine hippocampal slices for 3 days; the bottom panel consisting of six laser confocal microscopic images (scale bar: 10 μηι) depicts the differentiation human MPCs into Iba-1 -immunoreactive macrophages on hippocampal slices (bottom row). Iba-1 immunoreactivity is shown in the small left image of the row and human nuclei (HuNu) are shown in the small middle image of the row; the control population of CD34 + CD115 " cells did not give rise to human tissue macrophages (top row); Fig. 12a is a composite panel of six diagrams illustrating the results of the ex vivo differentiation of human MPCs; frozen mobilized human peripheral blood stem cells obtained by apheresis (G-CSF PBSC) were cultured in the presence of growth factors (IL-3, IL-6, SCF, Flt31igand and GM-CSF) in serum-free medium for 2 and 7 days. CD34 + CD45 + cells were plotted for CD 135 (unfilled histogram; middle row) and CD115 (unfilled histogram; bottom row) expression. Filled histograms showed immunostaining of isotype control. The G-CSF PBSC showed MPCs characteristics (CD135 + CD115 + ) after 7 day-culture in the presence of IL-3, IL-6, SCF, Flt31igand and GM-CSF;
Fig. 12b is a composite panel of three laser confocal microscopic images depicting the differentiation of human G-CSF PBSC-derived MPCs on mouse brain slices (= in the CNS environment) after 2 (upper image), 4 (middle image) and 7 (bottom image) days of co-culture. CFSE-labeled, human cells (white square) expressed Iba-1 from day 2, and the microglia-specific marker, P2Y12 receptor from day 4 in vitro, suggesting that the CNS environment mediates the differentiation of human MPCs into microglia-like cells. The right panel consisting of three small images shows a higher magnification image of the area indicated by the square in the confocal image (top image = CFSE + cells; middle image = Iba- 1 + cells and bottom image = P2RY12 + cells);
Fig. 12c is a composite panel of six laser confocal microscopic images indicating the differentiation of human MPCs that were cultured on poly-L-lysine-coated coverslips without mouse brain tissue. Cells were immunoreactive for Iba-1 (the left images of the upper row and the bottom row) and CD68 (the middle image of the bottom row), but not P2R.Y12 (the middle image of the upper row);
Fig. 13a is a diagram showing the overlapping of gene expression profiles of MACS-sorted human CD34 + cells after 7 days in vitro (hCD34 + , in vitro) with FACS-purified human MPCs in the absence (hMPCs, in vitro) or presence of murine hippocampal slices (hMPCs, in vitro + brain slice). Based on microarray analysis, a total of 2,816 genes were differently regulated between the three conditions;
Fig. 13b is a heat map diagram showing the gene expression profiles of MACS- sorted human CD34 + cells after 7 days in vitro (hCD34 + , in vitro) with FACS-purified human MPCs in the absence (hMPCs, in vitro) or presence of murine hippocampal slices (hMPCs, in vitro + brain slice). Genes which are involved in the regulation of inflammation and/or cell infiltration in the CNS such as CCR2, MMP8, CXCR4 are plotted; Fig. 13c is a panel of three diagrams indicating transplanted human MPCs that were detected in blood (left), bone marrow (middle) and spleen (right) of the recipient mice 14 days after transplantation. Very rare (max. of 0.01% viable cells) human cells were detected in the mouse circulation; and
Fig. 13d is a composite panel of two laser confocal microscopic images depicting the engraftment of human G-CSF PBSC-derived MPCs in the mouse facial nucleus 14 days after transplantation and facial nerve axotomy. Human cells (white square) expressed the macrophage markers Iba-1 and CD68. The right panel consisting of three small images shows a higher magnification image of the area indicated by the square in the confocal image (top image = Iba-1 + cells and middle image = human nuclei, HuNu + cells or human CD68 + cells).
Example 1: Materials and methods
If not indicated differently in the examples, the following materials and methods were used.
Mice. C57BL/6 mice were purchased from Charles River (Sulzbach, Germany). C57BL/6 mice expressing enhanced green fluorescent protein (EGFP) under the control of β-actin and Cx 3 CRl promoters were obtained from Charite Breeding Facility (Berlin, Germany). All donor and recipient mice were 7-12 weeks old at the time of bone marrow transplantation. All animal protocols were reviewed and approved by the state authorities (LaGeSo), Berlin, Germany.
Focal head irradiation and adoptive transfer experiments. Mice were anaesthetized by subcutaneous injection of a mixture of ketamine (75 mg/kg) and xylazine (15 mg/kg). Focal head irradiation (l lGy) was carried out using a Gammacell 40 Exactor (Theratronics). The body was protected from irradiation using a lead bar (3 cm thick). The total dose of γ- irradiation to the shielded areas was less than 0.6 Gy. To avoid acute irradiation-induced BBB damage, sorted cell populations were adoptively transferred 14 days after irradiation and one day after facial nerve axotomy (Fig. 1). Unilateral facial nerve axotomy was induced by transaction of the facial nerve at the stylomastoid foramen, resulting in ipsilateral whisker paresis. Subsequently, rapamycin (3 mg/kg) was administered for suppressing the graft rejection.
Cell sorting. Bone marrow-derived HSCs, MPCs, monocytes and granulocytes were sorted according to a published protocol (Kollet, O. et al., J. Clin. Invest. 112, 160-1698, 2003) with some modifications (see Fig. 7). MPCs from β-actin-EGFP transgenic mice were shown to have the same homing and differentiation characters as the ones isolated from the more widely used Cx 3 CRl GFP/+ donors (Hanna, R. N. et al, Nat. Immunol. 12, 778-785, 2011). Bone marrow from β-actin (ATCp)-EGFP transgenic mice was first enriched for monocytes and progenitors by negative selection with isolation kits according to the manufacturer's protocol (CD4, CD8a, CD 19 & Terl l9 custom-made cocktail for enrichment of progenitors and CDl lb+ populations; Miltenyi Biotec). Lineage-negative (Lin ) cells were isolated utilizing AutoMACS (Miltenyi Biotec) and subsequently stained for sca-1, CD 117, CD l ib, CD 1 15, Ly-6C, and Ly-6G. Cell sorting was performed on FACSAria II (BD Biosciences). HSCs were identified as lin " CDl lb ~ CD117 + Sca-l + ; MPCs were identified as lin CDl lb " CD115 + CD117 + ; inflammatory monocytes were identified as Lin CDl lb + CD 115 + Ly-6C hi ; granulocytes were identified as Lin CDl lb + CDl 15 " Ly6C int Ly-6G + (see Fig. 8).
Flow cytometry. Spleens were excised and pushed through a 70-μιη strainer, bone marrow cells were collected from both femurs and tibias, and blood was collected from Vena cava caudalis using a citrate-coated syringe. Red blood cells were lysed in Pharm LyseTM lysing buffer according to the manufacturer's protocol (BD Biosciences).
The following antibodies were used: sca-1 (D7); CD117 (2B8); CD115 (AFS98); Ly-6C (AL- 21 and HK1.4); CD4 (RM4-5); CD 8 (53-6.7); Ly6G (1A8); CDl lc (N418) (Biolegend) and CD1 lb (Ml/70) & B220 (RA3-6B2) (BD Pharmingen).
Forward- and side-scatter parameters were used for exclusion of doublets from analysis. Cellular fluorescence was assessed with MACSQuant (Miltenyi Biotec) and data were analyzed with Flow Jo software (TreeStar). Immunohistochemistry. Three, seven or fourteen days after an adoptive transfer, mice were anaesthetized. Peripheral blood was collected for flow cytometry. Subsequently, the animals were transcardially perfused with cold PBS. Spleen and bone marrow were then collected for flow cytometry. Brains were dissected, fixed in 4% paraformaldehyde (PFA) and cryoprotected with 30% sucrose. Coronal sections (30 μιη) of fixed tissues were obtained on a cryostat.
Sections were blocked at room temperature with 20% normal goat/donkey serum in TBS containing 0.3% Triton X-100 for 1 hr and washed three times in TBS. Incubation at 4 °C with anti-Iba-1 [1 :200] (Wako), anti-F4/80 [1 :200] (AbD Serotec), anti-GFP [1:200] (Invitrogen) or anti-human nuclei [1 :200] (Millipore) was performed overnight. After washing, sections were incubated with secondary antibodies (Alexa 488-/594-IgG 1:250; Invitrogen) at room temperature for 3 hrs. All antibodies were diluted in TBS containing 1% normal goat/donkey serum and 0.3% Triton X-100. Nuclei were counterstained with 4,6- diamidino-2-phenylindole (1 :10000; Sigma). The stained sections were examined using a fluorescence or laser confocal scanning microscope (Leica TCS SPE, Leica Microsystems).
Human MPCs. Leukapheresis was prepared from peripheral blood of healthy donors that were treated with granulocyte-colony stimulating factor (G-CSF). CD34+ hematopoietic stem/progenitor cells were isolated by MACS using CD34 MicroBead Kit UltraPure (Miltenyi Biotec). Isolated stem/precursor cells were subsequently cultured in the differentiation medium (serum-free medium (StemMACS, Miltenyi Biotec) containing IL-3 (20 ng/ml), IL-6 (20 ng/ml), SCF (50 ng/ml), Flt31igand (50 ng/ml), M-CSF (50 ng/ml) and GM-CSF (50 ng/ml). Fresh M-CSF (50 ng/ml) was added one time at day 3 in vitro. After 2, 4 and 7 days in vitro, cells were analysed by flow cytometry or were FACS-sorted and, subsequently, co- cultured on murine hippocampal slice or adoptive transferred into pre-conditioned recipients. All experiments with human material was approved by the ethics committee of the Charite- Universitatsmedizin Berlin and was performed only after obtaining the written informed consent from each donor.
Hippocampal slices and co-culturing. Hippocampal organotypic slice cultures were prepared from P4 - P9 C57BL/6 wild-type or CX3CRlgfp/+ mice as described previously (Stoppini L et al. J. Neurosci. Methods. 37: 173-182 (1991); Gogolla N et al. Nat. Protoc. 1 :1165-1171 (2006)). Briefly, hippocampi were dissected out aseptically and 350 μιη coronal slices were cut using a tissue chopper (Mcllwain tissue chopper, Vibratome Compagny). Slices were placed on Millicell culture inserts with 0.4 μπι pore size (Millipore) and maintained in a humidified 37°C, 5% C02 incubator. Slice media contained 50% Minimal Essential Medium with Earle's Salts; 25 % HEPES buffer, pH 7.2; 25% BME without Ca2+ and Mg2+; 25% horse serum; 2 mM L-Glutamine; and 0.65% Glucose. Medium was changed 24 h after dissection and every other day thereafter. The slices were cultured for 5-7 days before being used for experiments. Engraftment experiments in slices were performed by applying 5 x 103 of sorted HSCs or MPCs or 2 x 103 of sorted human cells onto the cultured hippocampal slices. After 7 days of co-culturing, slices were fixed in 4% paraformaldehyde (PFA) and analysed by immunohistochemistry. Number of cells transmigrating into the slices was counted using a fluorescence microscope (Leica TCS SPE, Leica Microsystems).
Gene expression analysis of hMPCs. The analysis was performed on three independent biological samples. After 7 days in vitro, CD34+ cells were isolated using CD34 MicroBead Kit UltraPure (Miltenyi Biotec) prior to FACS sorting. Sorted CD34+CD117+CD115+CD135+ cells (hMPCs) were then cultured in the presence of mouse hippocampal slices that were previously prepared on Millicell (Millipore) 5 days before coculturing. The control cells were hCD34+ collected directly after MACS and hMPCs that were culured in the absence of mouse brain slices. Seven days after co-culturing, hMPCs were harvested and total RNA was purified using RNeasy Micro Kit (Qiagen) according to the manufacturer's protocol. RNA integrity was determined using the 2100 Bioanalyzer (Agilent technologies, PA, USA) before analysis on Affymetrix Human/Mouse/Rat Gene LOST microarray. Microarray sample labeling, hybridization, scanning and subsequent data analysis were carried out by Laboratory of Functional Genome Research (Charite-Universitatsmedizin Berlin, Germany). Partek Genomics Suite 6.6 software (Partek, St. Louis, MO) was used for data visualization, statistical testing of affymetrix CEL files and quality control. Robust Multichip Average method was used for background correction and Quantile normalization (Irizzary RA et al. Biostatistics 4:249-264 (2003)). Summarization was performed using a median polish algorithm (Bolstad BM et al. Bioinfomatics 19:185-193 (2003)). For statistical analysis, we performed Analysis of Variance (ANOVA) in a multifactor experiment. A step up false discovery rate (FDR) was applied to P values from linear contrasts to determine a cutoff for significantly differentially expressed genes (Klipper-Aurbach Y et al. Med. Hypotheses. 45:486-490 (1995)). Pathway enrichment and gene ontology categories were retrieved from the database for annotation, visualization, and integrated discovery (Huang DW et al. Nat. Protoc. 4:44-57 (2009)). Enrichment was calculated with the modified Fisher's exact test (EASE) (Dennis C. Nature 421 :877-878 (2003); Hosack DA et al. Genome Biol. 4:R70 (2003).
Example 2: BM-derived MPCs give rise to brain macrophages
To identify the BM-derived cell population that is a precursor of brain macrophages, GFP + HSCs (Lin " c-kit + sca-l + CD1 15 " ; 10 5 cells), MPCs (Lin " c-kit hi sca-rCDl 15 + ; 10 5 cells), or inflammatory monocytes (CD4 " CD8a " CD19 " CDl lb + Ly6-C hi CDl 15 + ; 10 6 cells) (Figs. 7 and 8) were adoptively transferred into the recipient mice that were previously conditioned by focal head irradiation (1 lGy) and facial nerve axotomy as described previously (Bottcher, C. et al., PLoS One 8, e80260, 2013) (see Fig. la).
Engraftment of donor-derived cells at sites of damage, as well as in peripheral blood, spleen and bone marrow was analyzed at 1, 3, 7 and 14 days after adoptive transfer. As expected, only HSCs could repopulate the peripheral blood, spleen and bone marrow of recipients (see Fig. lb). On day 1 & 3 after transplantation, the vast majority of GFP + cells remained HSCs (see Fig. Ic). Of note, HSC-derived MPCs were detected in the bone marrow and spleen but not in the bloodstream of HSC-transplanted animals, suggesting that MPCs were not mobilized spontaneously from their bone marrow/spleen niche (see Fig. Id). Fourteen days after transplantation, donor-derived monocytes, granulocytes, CDl lb + CDl lc + macrophages and CDl lb " CDl lc DCs were detected in the spleen and bone marrow of mice that received GFP + HSCs (see Fig. le). Despite the highest presence of donor-derived cells in the circulation of recipient mice at any time point analyzed, adoptive transfer of BM-derived HSCs did not give rise to brain macrophages under our conditions (see Fig. 2b). In MPC-transplanted recipients, > 95% of donor-derived cells were found to express CDl lb at 24 hrs after adoptive transfer. As expected, they were identified as monocytes, dendritic cells and macrophages (see Fig. If) but not neutrophils. As early as 3 days after adoptive transfer, MPCs were able to give rise to brain macrophages that selectively engrafted in the lesioned facial nucleus, although < 0.5% of cells present in the host circulation expressed GFP (see Figs, lb and 2a). The cells engrafting in the CNS were immunoreactive for the macrophage markers, Iba-1 and F4/80, which ruled out a dendritic cell phenotype (see Figs. 2a and 9a). The number of GFP + cells at sites of brain damage increased with the progression of pathology (see Fig. 2c).
Up to 14 days after transplantation, none of Ly6C hl inflammatory monocytes gave rise to macrophages at sites of brain damage (see Fig. 2b). Notably, adoptively transferred monocytes were barely detected in the host circulation at any time point studied (see Fig. lb). To rule out that Ly6C hl monocytes missed a window of opportunity for CNS engraftment due to their short lifespan, Ly6C hl inflammatory monocytes were infused repeatedly over five consecutive days (10 6 cells per day) and CNS tissue was analyzed at 7 days after the first injection (d7). Although the number of GFP + cells in the bloodstream was significantly increased to a level comparable to that of MPC-transplanted mice (see Fig. 2d), no monocyte- derived cells were found in the axotomized facial nucleus (see Fig. 2d). Thus, BM-derived Ly6-C hl inflammatory monocytes are ineffective at engrafting in the lesioned CNS.
Next, the engraftment capacities of HSCs, MPCs and Ly6-C hl monocytes were assessed ex vivo using organotypic hippocampal slices. Again, MPCs showed a greater ability to engraft in the hippocampal slices compared to HSCs and inflammatory monocytes (see Fig. 2e).
Up to 14 days after adoptive transfer, CDPs (Lin " c-kit lo sca-l " CD115 + ; 10 5 cells), pre-cDCs (CD4 " CD8a " CD19 c-kit l0 CDl lb + CDl lc + CD115 + Cx 3 CRl + CD135 + ; 10 5 cells), myeloid precursors (MP; Lin ' c-kit hi sca-l " CDl 15 " ; 10 5 cells) or granulocytes (CD4 " CD8a " CD19 " CD1 lb + Ly6-C l0 Ly6-G + CDl 15 " ; 10 6 cells) did not give rise to GFP + donor-derived cells in the damaged CNS under these conditions (see Figs. 2b and 2c). Collectively, these results demonstrate that MPCs rather than other BM-derived cell populations are the precursors of brain macrophages.
Example 3: CNS recruitment of MPC-derived cells depends on CCR2 expression
Expression of the chemokine receptor CCR2 by bone marrow-derived cells is necessary for their engraftment in the CNS after myeloablative total body irradiation and bone marrow transplantation (Mildner, A. et al., Nat. Neurosci. 10, 1544-1553, 2007). To test whether MPCs exploit a CCR2-dependent mechanism for entry into the CNS, GFP + MPCs obtained from CCR2 7" mice were adoptively transferred into recipients that were conditioned by focal head irradiation and facial nerve axotomy. Up to 14d after adoptive transfer, no GFP + cells were found in the lesioned facial nucleus (see Fig. 3b). Homing to the spleen was reduced, but not abolished for CCR2-deficient MPCs (see Fig. 3a).
In spleen, MPCs underwent differentiation into macrophages and DCs as early as one day after transfer (see Figs, le and If), suggesting that MPCs may need to differentiate in the spleen to CCR2 + macrophages before entering the CNS. However, splenectomy resulted in higher numbers of MPC-derived cells in the lesioned facial nucleus, thereby dismissing the concept of peripheral priming in the spleen (see Figs. 3d and 3e).
Example 4: MPCs reduce amyloid load in a mouse model of Alzheimer's disease (AD)
In the next set of experiments, we wanted to assess whether the engraftment of MPC-derived cells at sites of brain damage would result in improved disease outcome in mouse models of chronic neurodegeneration such as Alzheimer's disease (AD; j APP swe/PSI , B6C3- Tg(APP695)3Dbo Tg(PSENl)5Dbo/J). 5xl0 5 GFP + MPCs were adoptively transferred into 9 month-old APP swe/ps l mice two weeks after focal head irradiation (see Fig. 4a). Four weeks after transplantation, GFP + cells were observed at perivascular sites (see Fig. 4b). Compared to non-transplanted APP swe PS1 animals, a significant reduction of both soluble and insoluble Αβι^ο and Αβ 1-42 was observed in the brains of MPC-treated APP swe/PS1 mice (see Fig. 4c). Thus, the data suggest that MPC-derived perivascular macrophages are involved in the clearance of Αβ from the CNS.
Example 5: Transplantation of MPCs after disease onset attenuates disease progression in a mouse model of amyotrophic lateral sclerosis (ALS)
Overexpression of the mutant SOD1 (G93A) gene in mice leads to progressive neurodegeneration and neuroinflammation (Gurney, M. E. et al., Science 264, 1772-1775, 1 994; Boillee, S. et al. Neuron 52, 39-59, 2006), as well as degeneration of mesodermal tissues such as skeletal muscle and heart (Corti, S. et al. Brain 127, 2518-2532, 2004), thereby mimicking a familial form of amyotrophic lateral sclerosis (ALS). Transplantation of bone marrow cells expressing the wild type SOD1 gene into SODl G93A transgenic mice (B6.Cg-Tg(SODl -G93A) dl IGur/J) after total body irradiation resulted in a delay of disease onset and increase of life span (Corti, S. et al. Brain 127, 2518-2532, 2004). These wild type BM cells also participated in muscle regeneration (Corti, S. et al. Brain 127, 2518-2532, 2O04).
Since the pathological hallmarks of ALS are degeneration/inflammation of both the CNS (motor neurons in the cortex and spinal cord) and the periphery (sciatic nerve and muscle), we assessed potential therapeutic effects of wild type MPCs in SODl G93A transgenic mice. After disease onset (90-100 days of age), 5xl0 5 MPCs from ΑΤΟβ-EGFP transgenic mice were adoptively transferred into non-irradiated SODl G93A transgenic mice. Four weeks after transplantation, a significant reduction of inflammation (indicated by the activation of microglia/macrophages) was observed in the spinal cord and sciatic nerve (see Fig. 5a).
Up to 10 weeks after a single intravenous injection of GFP + MPCs, recruitment of MPC- derived macrophages was stably detected in the sciatic nerve and hindlimb muscles of the recipients (see Figs. 5e and 5f). Although GFP + cells were never detected in the brain or spinal cord, MPC administration resulted in improved motor function (see Figs. 5b and 5d), as well as prolongation of disease onset (~ 29%) and progression (~ 60%) compared to the non- transplanted SODl G93A transgenic mice (see Fig. 5c). Recruitment of MPC-derived macrophages to the sciatic nerve was associated with reduced inflammation and macrophage accumulation (see Fig. 5g), a hallmark of ALS (Dibaj, P. et al. PLoS ONE 6, el7910, 2011; Graber, D. J. et al. J Neuroinflammation 7, 8, 2010; Chiu, I. M. et al. Proc. Natl. Acad. Sci. U.S.A. 106, 20960-20965, 2009). Slight attenuation of microglial activation in the spinal cord was also observed in this long-term study but did not reach statistical significance (see Fig. 5g). However, MPC administration resulted in dramatically reduced expression of proinflammatory mediators like CCL2, TNF-a, TGF-β, IL-6 and IL-4 mRNAs in the spinal cords of SODl G93A transgenic mice (see Fig. 5h).
In the past, transplantation of SOD1 mutant bone marrow cells into total body irradiated SODl G93A transgenic mice did not result in an improvement of disease outcome whereas this was the case with wild type bone marrow cells (Corti, S. et al. Brain 127, 2518-2532, 2004). We confirmed these findings using MPCs; adoptive transfer of 5xl0 5 purified SOD1 mutant MPCs into SODl G93A transgenic mice failed to confer protection, while disease progression was attenuated in SODl G93A transgenic mice after adoptive transfer of wild type MPCs (see Figs. 6a-c).
Example 6: Characterization of human bone marrow-derived myeloid progenitor cells (hMPCs) from mobilized peripheral blood
CD34-positive hematopoietic stem cells were isolated from mobilized peripheral blood (a frozen apheresis product) by means of magnetic-activated cell sorting (MACS). After sorting, the cells were characterized by flow cytometry. As indicated in Fig. 10a, no MPCs (SSC l0 FSC l0 CD45 l0 CD34 + CDl 15 + ) were detected in the sorted cell population.
Isolated stem cells (SSC lo FSC lo CD45 lo CD34 + CDl 15 " ) were subsequently cultured in the presence of growth factors (IL-3, IL-6, SCF, Flt31igand and GM-CSF) in serum-free medium. After three days of culture, the cells were harvested and analyzed by flow cytometry. The majority of living cells were identified as SSC lo FSC lo CD45 lo CD34 + (98.7 % of the entire cell population). 79.5 % of the SSC lo FSC lo CD45 lo CD34 + cell population expressed MPC markers, such as CD115 (CSF-1R), after differentiation in culture (see Fig. 10b). Example 7: Differentiation of sorted human bone marrow-derived myeloid progenitor cells (hMPCs)
Frozen mobilized human peripheral blood stem cells obtained by apheresis (G-CSF PBSC) were cultured in the presence of growth factors (IL-3, IL-6, SCF, Flt31igand and GM-CSF) in serum-free medium for 3 days (see Fig. 11). Cells were then sorted using flow cytometry. hMPCs were isolated as SSC lo FSC lo CD34 + c-kit + CD115 + CD135 + cells. SSC lo FSC lo CD34 + c- kit ' CDl 15 " CD135 ~ cells served as a negative control population. The sorted cells (2x10 cells) were then cultured on the murine hippocampal slices for 3 days. We observed that hMPCs expressing the human nuclear antigen differentiated into Iba-l-immunoreactive macrophages on hippocampal slices. This was not observed for CD34 + CD115 " control cells.
Example 8: Ex vivo expansion and differentiation of human analogue MPCs and their responses to CNS microenvironment.
Human CD34 + hematopoietic cells were isolated by magnetic-activated cell sorting from G- CSF mobilized peripheral blood (apheresis sample). MACS-sorted CD34 + cells were cultured in the GMP-grade differentiation medium (serumfree medium containing cytokine cocktail). Two days in differentiation medium (days in vitro), we detected no CD34 + cells that express MPC markers like CD115 and CD 135. At 7 days in vitro the SSC lo FSC lo CD45 ,0 CD34 + CD115 + CD135 + cell population was detected. The results obtained are shown in Fig. 12 a.
Human analogue MPCs were cultured in the differentiation medium for 2, 4 and 7 days. Cells were harvested and labeled carboxyfluorescein (CFSE) prior to co-culturing on the murine hippocampal slices. Three days after co-culture, Iba-1 + CFSE + cells were detected in all conditions (2, 4 and 7 d) but Iba-1 + CFSE + P2YR12 + microglia-like cells were only detected in the 4 and 7 d samples. Iba-1 is shown in the middle high resolution image, CFSE in the upper high resolution image and P2YR12 in the bottom high resolution image. The results obtained are shown in Fig. 12b. Human analogue MPCs cultured in the differentiation medium for 4 days were cultured on the coverslip. After three days, Iba-1 + and CD68 + macrophages were detected but none were positive for microglia marker P2YR12. Iba-1 is shown in the left image of each row, CD68 in the middle image of the bottom row and P2YR12 in the middle image of the top row. Scale bar: 100 μηι. The results obtained are shown in Fig. 12c.
The CNS environment mediates the differentiation of human MPCs into microglia-like cells.
Exampe 9: Human MPCs target sites of brain damage.
Fig. 13a shows a Venn diagram depicting the different regulated and overlapping genes (in total of 2816 genes) between MACS-sorted hMPCs and hMPCs cultured with and without murine brain slices (One-way ANOVA, false discovery rate (FDR) p < 0.05).
Fig. 13b shows an mRNA expression profile of selected genes that involve in transendothelial and anti-inflammatory activities (One-way ANOVA, FDR p < 0.05, fold change > 2 or < -2). The genes such as CCR2, MMP8 and CXCR4 are up regulated in human MDPs cultured with mouse hippocampal slices.
Fig. 13c shows the results of FACS analysis of gated viable cells in peripheral blood, bone marrow (BM) and spleen of mice received i.v. injection of MACS-sorted 1x105 hMPCs at 14 days after transplantation. Very rare human CD45 + cells were detected (n = 3).
Fig. 13d is a series of laser confocal microscopic images (scale bar: 100 μπι) showing hMPC- derived cells detected in the lesioned facial nuclei of mice that were intravenously injected with FACS-sorted lxl 0 5 hMPCs at 14 days after transplantation (n = 3). The hMPC-derived cells are stained with either antibody against human nuclei (the middle high resolution image in the top image) or human CD68 (the middle high resolution image in the bottom image). The microglia/m<I> markers, Iba-1, is shown in the top high resolution image of each image. Human MPCs are able to engraft in the conditioned CNS, thus promising to apply for therapy in the neurodegenerative disorders.
The features of the present invention disclosed in the specification, the claims, the sequence listing and/or the drawings may both separately and in any combination thereof be material for realizing the invention in various forms thereof.